Clinicopathologic study of invasive micropapillary carcinoma of the breast.

Oncotarget

Department of Breast Surgery, West China Hospital/West China School of Medicine, Sichuan University, 610041, P.R. China.

Published: June 2017

Invasive micropapillary carcinoma (IMPC) is a rare subtype of breast carcinoma. It is presumed to be more aggressive than invasive ductal carcinoma (IDC), though it is uncertain whether the prognoses of IMPC and IDC differ. In this retrospective study, we compared the clinicopathologic characteristics and survival between 170 female patients with IMPC (pure or mixed with IDC) and 728 with pure IDC. The IMPC patients had higher clinical stages and histologic grades, higher incidences of lymphovascular invasion and axillary lymph node extracapsular extension, and a higher degree of lymph node involvement than IDC patients. Moreover, IMPC was associated with increases in estrogen receptor (ER) and progesterone receptor (PR) positivity and HER-2 overexpression. Although locoregional recurrence-free survival (LRRFS) and recurrence-free survival (RFS) were poorer in IMPC patients than IDC patients, overall survival and distant metastasis survival did not differ between the two groups. Multivariate analysis revealed that IMPC was an independent prognostic factor for LRRFS in breast cancer, and IMPC patients had poorer clinicopathologic characteristics and poorer RFS and LRRFS than IDC patients. We therefore suggest that to improve treatment decisions, patients with breast carcinoma be tested for the presence of this specific subtype.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522079PMC
http://dx.doi.org/10.18632/oncotarget.16405DOI Listing

Publication Analysis

Top Keywords

impc patients
12
idc patients
12
invasive micropapillary
8
micropapillary carcinoma
8
impc
8
breast carcinoma
8
clinicopathologic characteristics
8
patients
8
patients impc
8
lymph node
8

Similar Publications

Deciphering the composition and key driver genes of breast invasive micropapillary carcinoma by multi-omics analysis.

iScience

November 2024

Department of Minimally Invasive Esophageal Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

In this study, we delved into the intrinsic cellular components and transcriptomic signatures characterizing breast-invasive micropapillary carcinoma (IMPC). Employing bulk RNA sequencing, we conducted differential gene expression and functional profiles across breast cancer tissues. Single-cell transcriptome sequencing was performed on mixed IMPC samples.

View Article and Find Full Text PDF

Predictive model of prognosis index for invasive micropapillary carcinoma of the breast based on machine learning: a SEER population-based study.

BMC Med Inform Decis Mak

September 2024

Department of Breast Surgery, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, No.420, Fu Ma Road Jinan District, Fuzhou, Fujian Province, 350011, China.

Background: Invasive micropapillary carcinoma (IMPC) is a rare subtype of breast cancer. Its epidemiological features, treatment principles, and prognostic factors remain controversial.

Objective: This study aimed to develop an improved machine learning-based model to predict the prognosis of patients with invasive micropapillary carcinoma.

View Article and Find Full Text PDF

Background: Pralsetinib, a targeted inhibitor of the RET enzyme, plays a critical role in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by RET gene fusion mutations following platinum-based chemotherapy. Nevertheless, impurities resulting from the manufacturing and degradation of pralsetinib have the potential to impact its therapeutic effectiveness and safety profile.

Methods: To address this issue, a liquid chromatography method was developed and validated for the specific identification of pralsetinib and its related impurities.

View Article and Find Full Text PDF

Background: Invasive micropapillary carcinoma (IMPC) was first proposed as an entity by Fisher et al. In the 2003 World Health Organization (WHO) guidelines for histologic classification of the breast tumors. IMPC was recognized as a distinct, rare histological subtype of breast cancer.

View Article and Find Full Text PDF
Article Synopsis
  • Invasive micropapillary carcinoma (IMPC) of the breast is known for its aggressive characteristics like lymphovascular invasion and unique growth patterns, but its underlying molecular mechanisms are not well understood.* -
  • This study investigated the roles of miR-30c and MTDH in IMPC through various experimental methods, finding that miR-30c acts as a tumor suppressor by inhibiting cell growth, invasion, and polarity changes by directly targeting MTDH.* -
  • The research suggests that the miR-30c/MTDH axis could serve as both a therapeutic target and a prognostic biomarker for IMPC, highlighting its correlation with key clinical factors like tumor size and patient survival.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!